Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer - Concepedia

Concepedia

Publication | Open Access

Efficacy and safety of first-line pembrolizumab monotherapy in elderly patients (aged ≥ 75 years) with non-small cell lung cancer

DOI Full Paper Access

30

Citations

23

References

2019

Year

Hisao Imai, Satoshi Wasamoto, Ou Yamaguchi, Kensuke Suzuki, Tomohide Sugiyama, Junji Uchino, Hiroyuki Minemura, Takashi Osaki, Hisashi Ishii, Yukihiro Umeda,

Journal of Cancer Research and Clinical Oncology

Geriatric OncologyOncologyElderly PatientsCancer ManagementImmune Checkpoint InhibitorFirst-line Pembrolizumab MonotherapyPharmacotherapyCancer TreatmentMedicineRadiation OncologyLung Cancer

References

	Year	Citations

Page 1

Page 1